Is there a role for treatment of asthma with omalizumab?

Archives of Disease in Childhood

Volumn 88, Issue 1, 2003, Pages 71-74

  Milgrom, H ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; CORTICOSTEROID; FC RECEPTOR; IMMUNOGLOBULIN E; NEDOCROMIL; OMALIZUMAB;

ASTHMA; ATOPY; CELL ACTIVATION; DOSE RESPONSE; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOREGULATION; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN TEST; TH2 CELL;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; HUMANS; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; MAST CELLS;

EID: 0037235317     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.1.71     Document Type: Review

References (55)

1. Shamssain MH, Shamsian N. Prevalence and severity of asthma, rhinitis, and atopic eczema: the north east study. Arch Dis Child 1999;81:313-17.
2. Kaur B, Anderson HR, Austin J, et al. Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK). BMJ 1998;316:118-24.
3. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233-48, quiz 248-52.
4. Sly RM. Decreases in asthma mortality in the United States. Ann Allergy Asthma Immunol 2000;85:121-7.
5. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 1992;13:95-100.
6. Milgrom H. Drug treatment of wheezy infants. In: David T, ed. Recent advances in paediatrics. London: Churchill Livingstone, 2001:27-42.
7. Illi S, von Mutius E, Lau S, et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol 2001;108:709-14.
8. Haby MM, Peat JK, Marks GB, et al. Asthma in preschool children: prevalence and risk factors. Thorax 2001;56:589-95.
9. Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001;108:720-5.
10. Holt PG, Macaubas C, Stumbles PA, et al. The role of allergy in the development of asthma. Nature 1999;402(6760 suppl):B12-17.
11. Martinez FD. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol 1999;104(4 pt 2):169-74.
12. Holgate ST, Frew AJ. Choosing therapy for childhood asthma. N Engl J Med 1997;337:1690-2.
13. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100:44-51.
14. Redington AE, Howarth PH. Airway wall remodelling in asthma. Thorax 1997;52:310-12.
15. Helms PJ. Early environmental influences in the development of asthma and atopic disease. Monaldi Arch Chest Dis 2001;56:265-9.
16. GINA. Practical guide for asthma management, http://www.ginasthma.com:80/xprac.html, 1995.
17. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Publication No. 97-4051, 1997.
18. British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52:S1-21.
19. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol 1998;25:1-17.
20. Stein RT, Holberg CJ, Morgan WJ, et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax 1997;52:946-52.
21. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001;344:30-7.
22. Kemeny DM, Urbanek R, Ewan P, et al. The subclass of IgG antibody in allergic disease: II. The IgG subclass of antibodies produced following natural exposure to dust mite and grass pollen in atopic and non-atopic individuals. Clin Exp Allergy 1989;19:545-9.
23. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991;12:256-7.
24. Ebner C, Schenk S, Najafian N, et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995; 154:1932-40.
25. Till S, Durham S, Dickason R, et al. IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression. Immunology 1997;91:53-7.
26. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-62.
27. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a saurce of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-80.
28. Pawankar RU, Okuda M, Hasegawa S, et al. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Am J Respir Crit Care Med 1995;152(6 pt 1):2059-67.
29. Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999;104:829-35.
30. Ying S, Barata LT, Meng Q, et al. High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen- induced late-phase cutaneous reactions in atopic subjects. Immunology 1998;93:281-8.
31. Sihra BS, Kon OM, Grant JA, et al. Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: relationship to total serum IgE concentrations. J Allergy Clin Immunol 1997;99:699-706.
32. Rajakulasingam K, Durham SR, O'Brien F, et al. Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J Allergy Clin Immunol 1997;100:78-86.
33. Armitage RJ, Goff LK. Functional interaction between B cell subpopulations defined by CD23 expression. Eur J Immunol 1988;18:1753-60.
34. Menz G, Ying S, Durham SR, et al. Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma. Allergy 1998;53:15-21.
35. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group. Am Rev Respir Dis 1993;148:1252-7.
36. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group. Eur Respir J 1994;7:63-8.
37. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999;14:892-6.
38. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63.
39. Holt PG, Sly PD. Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs. Thorax 2000;55:700-3.
40. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Intern Arch Allergy Immunol 1995;107:308-12.
41. Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
42. Presta L, Gorman C, Shields R, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:26368-73.
43. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45.
44. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62.
45. Milgrom H. Attainments in atopy: special aspects of allergy and IgE. Adv Pediatr. In press.
46. Boulet L, Chapman K, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40.
47. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 1999;341:1966-73.
48. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
49. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
50. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
51. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25 an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9.
52. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286:2956-67.
53. Holgate ST, Lackie PM, Howarth PH, et al. Invited lecture: activation of the epithelial mesenchymal trophic unit in the pathogenesis of asthma. Int Arch Allergy Immunol 2001;124:253-8.
54. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994;93:33-9.
55. Milgrom H, Bender B, Ackerson L, et al. Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-7.